Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Medicine Co., Ltd.
和譽醫藥有限責任公司
(formerly known as Abbisko Cayman Limited 和譽開曼有限責任公司)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

CHANGE OF COMPANY NAME

References are made to the announcement of Abbisko Medicine Co., Ltd. (formerly known as "Abbisko Cayman Limited") (the "**Company**") dated 24 August 2026, the circular (the "**Circular**") and the notice of the extraordinary general meeting (the "**EGM**") of the Company both dated 28 August 2026 and the poll results announcement of the EGM dated 17 September 2026 in relation to, among others, the proposed Change of Company Name.

Capitalized terms and expressions used in this announcement shall have the same meanings as those defined in the Circular unless otherwise stated.

CHANGE OF COMPANY NAME

The Board is pleased to announce that following the passing of a special resolution approving the proposed Change of Company Name by the Shareholders at the EGM held on 17 September 2026, the certificate of incorporation on change of name was issued by the Registrar of Companies in the Cayman Islands certifying that the English name of the Company has been changed from "Abbisko Cayman Limited" to "Abbisko Medicine Co., Ltd." and the dual foreign name in Chinese of the Company from "和譽開曼有限責任公司" to "和譽醫藥有限責任公司", with effect from 18 September 2026.

The Certificate of Registration of Alteration of Name of Registered Non-Hong Kong Company was issued by the Registrar of Companies in Hong Kong on 15 October 2026 certifying that the English name of the Company registered in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the laws of Hong Kong) was changed from "Abbisko Cayman Limited" to "Abbisko Medicine Co., Ltd." and the Chinese name was changed from "和譽開曼有限責任公司" to "和譽醫藥有限責任公司".

EFFECT OF THE CHANGE OF COMPANY NAME

The Change of Company Name will not affect any of the rights of the Shareholders and the trading of the shares (the "**Shares**") of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Moreover, the Change of Company Name will not, of itself, affect the rights of any Shareholders or the Company's daily business operation and its financial position.

All existing share certificates of the Company bearing the former name of the Company will continue to be valid evidence of title to the Shares and will continue to be valid for trading, settlement, registration and delivery purposes. As such, no arrangement will be made for the exchange of the existing share certificates of the Company for the new share certificates bearing the Company's new name as a result of the Change of Company Name. With effect from 9 November 2026, share certificates of the Company will only be issued in the new name of the Company.

For the avoidance of doubt, the English and Chinese stock short names of the Company for trading in the Shares on the Main Board of the Stock Exchange will remain unchanged as "ABBISKO-B" and "和譽-B", respectively. The stock code of the Company will remain unchanged as "2256". The Company's website will also remain unchanged.

By order of the Board
Abbisko Medicine Co., Ltd.
Dr. Xu Yao-Chang
Chairman

Shanghai, November 2, 2026

As at the date of this announcement, the Board comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.